ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
24 oct. 2023 04h00 HE
|
AKAMPION
Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress...
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
17 oct. 2023 04h00 HE
|
AKAMPION
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors ...
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
19 sept. 2023 04h00 HE
|
AKAMPION
- Former Novartis Executive Director brings significant expertise in manufacturing, operations, and technical development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA –...
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
24 mai 2023 04h00 HE
|
AKAMPION
- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...
ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
25 avr. 2023 04h00 HE
|
AKAMPION
- Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 –...
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
12 avr. 2023 08h00 HE
|
AKAMPION
Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material...
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
17 janv. 2023 04h00 HE
|
AKAMPION
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...